Learning Objectives:

1.  Familiarize ourselves with the immune microenvironment in AML
2.  Appraise the major clinical studies evaluating immune checkpoint inhibitors against the PD-1/PD-L1 axis, in 
     the management of AML
3.  Identify key areas of unmet need in the study of immune checkpoint inhibitors in the management of AML

Session date: 
03/24/2022 - 8:00am to 9:00am CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Athalia Pyzer, MD